Wall Street brokerages predict that Radius Health Inc (NASDAQ:RDUS) will post $40.49 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Radius Health’s earnings, with estimates ranging from $37.59 million to $43.00 million. Radius Health reported sales of $22.63 million in the same quarter last year, which indicates a positive year over year growth rate of 78.9%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, August 6th.
On average, analysts expect that Radius Health will report full-year sales of $170.30 million for the current year, with estimates ranging from $167.05 million to $174.00 million. For the next year, analysts anticipate that the firm will report sales of $236.55 million, with estimates ranging from $205.71 million to $256.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Radius Health.
Radius Health (NASDAQ:RDUS) last released its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.95) by $0.01. The firm had revenue of $29.84 million for the quarter, compared to analyst estimates of $35.35 million. Radius Health had a negative return on equity of 233.12% and a negative net margin of 176.84%. The business’s revenue for the quarter was up 105.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.11) earnings per share.
In other news, Director Debasish Roychowdhury sold 4,800 shares of the company’s stock in a transaction that occurred on Thursday, April 11th. The stock was sold at an average price of $22.15, for a total value of $106,320.00. Following the transaction, the director now owns 5,500 shares of the company’s stock, valued at $121,825. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Willard H. Dere sold 1,680 shares of the company’s stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $22.22, for a total value of $37,329.60. Following the completion of the transaction, the director now directly owns 8,620 shares in the company, valued at approximately $191,536.40. The disclosure for this sale can be found here. 4.00% of the stock is currently owned by corporate insiders.
A number of large investors have recently modified their holdings of RDUS. Wellington Management Group LLP grew its position in Radius Health by 7.5% during the first quarter. Wellington Management Group LLP now owns 3,859,878 shares of the biopharmaceutical company’s stock worth $76,966,000 after buying an additional 270,676 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in Radius Health by 1,624,525.0% during the first quarter. PNC Financial Services Group Inc. now owns 259,940 shares of the biopharmaceutical company’s stock worth $5,183,000 after purchasing an additional 259,924 shares during the last quarter. Norges Bank bought a new stake in Radius Health during the fourth quarter worth $4,057,000. DekaBank Deutsche Girozentrale lifted its stake in Radius Health by 1,098.7% during the first quarter. DekaBank Deutsche Girozentrale now owns 189,400 shares of the biopharmaceutical company’s stock worth $3,739,000 after purchasing an additional 173,600 shares during the last quarter. Finally, BB Biotech AG lifted its stake in Radius Health by 1.8% during the fourth quarter. BB Biotech AG now owns 6,710,276 shares of the biopharmaceutical company’s stock worth $110,652,000 after purchasing an additional 120,000 shares during the last quarter.
NASDAQ:RDUS opened at $21.22 on Wednesday. The company has a debt-to-equity ratio of 6.75, a quick ratio of 5.04 and a current ratio of 5.16. The company has a market capitalization of $999.67 million, a price-to-earnings ratio of -4.35 and a beta of 0.99. Radius Health has a 12-month low of $12.81 and a 12-month high of $31.92.
About Radius Health
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.
Recommended Story: How do candlesticks reflect price movement?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.